Barrington Maintains Lifecore Biomedical(LFCR.US) With Hold Rating
Craig-Hallum Maintains Lifecore Biomedical(LFCR.US) With Buy Rating
Lifecore Biomedical Analyst Ratings
Craig-Hallum Initiates Lifecore Biomedical(LFCR.US) With Buy Rating, Announces Target Price $8
Barrington Downgrades Lifecore Biomedical(LFCR.US) to Hold Rating
Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9
Lifecore Biomedical Analyst Ratings
Barrington Trims Price Target on Lifecore Biomedical to $10 From $11, Maintains Outperform Rating
Barrington Raises Price Target on Lifecore Biomedical to $11 From $10, Keeps Outperform Rating
Barrington Keeps Their Buy Rating on Lifecore Biomedical (LFCR)
Barrington Remains a Buy on Lifecore Biomedical (LFCR)
Analyst Ratings for Lifecore Biomedical
Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8
Barrington Cuts Price Target on Lifecore Biomedical to $8 From $10, Keeps Outperform Rating
Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2
Analysts Offer Insights on Healthcare Companies: Lifecore Biomedical (LFCR), Prestige Consumer Healthcare (PBH) and Quest Diagnostics (DGX)